Keiko Nakano

Oct 20, 2023 | mdpi.com | Keiko Nakano |Michiyo Okamoto |Azusa Takahashi-Nakaguchi |Kaname Sasamoto

1. IntroductionThe threat of antimicrobial resistance (AMR) has progressed in parallel with the COVID-19 pandemic caused by the SARS-CoV-2 virus [1]. These resistant pathogens include drug-resistant Candida [1,2,3]. In recent years, drug-resistant Candida species other than Candida albicans, called non-albicans Candida, have become more common, especially Candida glabrata. Therefore, the development of new antifungal agents against them is urgently needed [4,5,6].

Oct 1, 2023 | sciencedirect.com | Keiko Nakano |Hideki Nakano

IntroductionChronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder marked by outgrowths of sinonasal mucosa leading to nasal blockage, olfactory dysfunction, and subsequent impairments in quality of life.

Oct 1, 2023 | sciencedirect.com | Scott Smith |Keiko Nakano |Hideki Nakano

Section snippetsFood allergy pathologyThe development of food allergy involves complex interactions between multiple types of immune cells, including CD4+ TH cells, mast cells, basophils, and antigen-presenting cells (APCs) such as dendritic cells (DCs) and B cells.

Oct 1, 2023 | sciencedirect.com | Keiko Nakano |Hideki Nakano

This work was supported in part by the Division of Intramural Research program of the National Institute of Allergy and Infectious Diseases at the NIH. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of

Sep 4, 2023 | sciencedirect.com | Keiko Nakano |Hideki Nakano

Section snippetsStudy design and participantsSamples from 470 children younger than 13 years were obtained from participants enrolled onto previously described cohorts from 3 different sites: site 1 (Stanford, Calif),31, 32, 33 site 2 (Fresno, Calif),34 and site 3 (CHU Lille and Hauts-de-France, France)35, 36, 37 (Fig 1). All participants’ parents/caregivers consented via an institutional review board–approved protocol (Stanford University for sites 1 and 2, CPP Nord-Ouest IV for site 3).